MLD 1-16-03	[1662/54802
O1-17-2003  S. DEPARTMENT OF COMMERCE  102336564	
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof	
Name of conveying party(ies):     Teva Pharmaceutical Industries Ltd.	Name and address of receiving party(ies)     Name: <u>Teva Pharmaceutical USA</u> , <u>Inc.</u>
Additional name(s) of conveying parties attached? □ Ycs x No	Street Address: 1090 Horsham Road, P.O. Box 1090
3. Nature of conveyance:  x Assignment	City: North Wales, Pennsylvania 19454-1090
4. Application numbers or patent numbers:  If this document is being filed together with a new application, the execution date of the application is:  -	
A. Patent Application: 09/916,885	B. Patent No.(s)
Additional Numbers attached? □ Yes X No	
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 1
Name: Steven J. Lec Internal Address: KENYON & KENYON	7. Total fee (37 C.F.R. 3.41)
Street Address: One Broadway City: New York State: New York ZIP: 10004	8. Deposit account number: 11-0600
DO NOT USE THIS SPACE	
9. Statement and signature.  To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.	
Paul Johnson (Reg. No. 35,559)  Name of Person Signing  Paul Johnson (Reg. No. 35,559)  Signature	Octobe 29, 2001 Date
Total Number of pages including cover sheet, attachments, and document: 2	
OMB No. 0651-0011 (exp. 4/94)	
Do not detach this portion  Mail documents to be recorded with required cover sheet information to:	
Commissioner of Patents and Trademarks Box Assignments Washington DC 20231	
417229	

PATENT REEL: 013365 FRAME: 0287

1662/54802

## **ASSIGNMENT**

WHEREAS TEVA PHARMACEUTICAL INDUSTRIES LTD., having a place of business at 5 Basel Street, P.O. Box 3190, Petah Tiqva 49131, Israel, hereinafter called "Assignor," is the owner of the entire right, title, and interest in and to inventions and discoveries in OXIDATION METHOD FOR PREPARING HIGHLY PURE MODAFINIL, CRYSTALLINE FORMS OF MODAFINIL, AND METHODS OF PREPARING THE CRYSTALLINE FORMS (hereinafter, "the Invention"), described in U.S. Patent Application Serial No. 09/916,885, filed on July 27, 2001, and

WHEREAS TEVA PHARMACEUTICALS USA, INC., having a place of business at 1090 Horsham Road, P.O. Box 1090, North Wales, Pennsylvania 19454-1090, United States of America, hereinafter called "Assignee," is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited,

NOW, THEREFORE, for good and valuable consideration furnished by Assignee, receipt and sufficiency of which is hereby acknowledged, Assignor hereby, without reservations,

- 1. Assigns, transfers, and conveys to Assignee the entire right, title, and interest in and to the Invention in, and only in, the nation and territory of **Barbados**, and in and to any **Barbados** national patent that may issue for the Invention; and
- Authorizes Assignee to file, under the International Convention or otherwise, for patent protection for the Invention within the nation and territory of Barbados.

TEVA PHARMACEUTICAL INDUSTRIES LTD.

Signature:

Date:

Name of Person Signing:

Yehudah Livneh

Director of Patents

Signature:

Date:

Name of Person Signing:

Meron Mann

Vice President - Chemicals

NY01 401807 v 1

RECORDED: 01/16/2003

PATENT REEL: 013365 FRAME: 0288